The Growing Challenge of Antifungal Drug Development
Antimicrobial resistance is a critical global health concern, often focused on bacteria. However, fungal pathogens pose a distinct and increasingly urgent threat. Developing new antifungal drugs is proving remarkably difficult, due to the biological similarities between fungi and humans, leading to a limited treatment pipeline and increasing concerns about resistance.
Why Antifungal Drug Development is So Difficult
According to John Rex, MD, Chief Medical Officer at F2G Ltd, the core challenge lies in the fundamental biology of fungi. “Finding antifungal drugs is hard because we’re so closely related to the fungi. Eukaryotes are eukaryotes,” he explained in an interview with Infection Control Today®. This means that fungi share much of the same cellular machinery as human cells, making it difficult to identify targets that will selectively harm the fungus without similarly harming the patient. Source
Unlike bacteria, which have several unique structures, fungi’s similarities to human cells limit potential drug targets. “There are several systems in bacteria that are different from those in human beings. It’s been relatively easier to uncover nonhuman targets in bacteria than in fungi.” The cell wall remains one of the few viable targets, as humans do not possess cell walls. However, beyond this, options are limited.
The Danger of Invasive Fungal Infections
The difficulty in treating invasive fungal infections is compounded by the vulnerability of patients who contract them. Dr. Rex emphasizes that these infections typically occur in individuals with compromised immune systems. Source While fungi are ubiquitous – constantly present in our environment – a healthy immune system usually provides adequate defense. However, when an infection takes hold, it indicates a significant underlying vulnerability.
Fungi are biologically adapted to degrade tissue. “Biologically, what fungi do for a living is degrade dead tissue. When they get going in you, most fungal infections involve you becoming meaningfully more vulnerable in some way.”
Limited Treatment Options and the Rise of Resistance
Current antifungal drugs tend to inhibit fungal growth rather than kill the fungus outright, making them “static” rather than “cidal.” Treatment options for invasive fungal infections like Candida and Aspergillus are narrow, with only a few classes of licensed antifungal agents available: azoles, echinocandins, and amphotericin variations. Source
resistance patterns within each class are often widespread. Resistance to one azole typically means resistance to all azoles, and the same applies to echinocandins. This lack of diversification limits therapeutic flexibility when infections become resistant.
The Potential of Combination Therapy
Combination therapy, commonly used for tuberculosis and HIV, has a more limited role in fungal disease. Theoretical benefits include synergy (where the combination is more effective than either drug alone), overlap (providing coverage when susceptibility is uncertain), and mutual protection (preventing resistance by using multiple agents). However, demonstrating synergy in fungal infections is challenging, and the rate of resistance development is relatively low compared to tuberculosis.
A Thin Pipeline and the Role of AI
The antifungal drug pipeline is alarmingly small, with only a single-digit number of potential drugs in clinical development, compared to the double-digit numbers for antibacterials and the thousands for cancer therapies. Source Several factors contribute to this, including the difficulty of finding new antifungal targets and the challenges of conducting clinical trials in relatively uncommon and severe infections.
Artificial intelligence (AI) offers potential for accelerating drug discovery, but Dr. Rex cautions that simply identifying antimicrobial activity is not enough. A viable drug must also be safe, reach the infection site, and maintain its activity. AI needs to be trained to consider these drug-like characteristics. Despite these challenges, he remains optimistic about the potential of AI to contribute to the development of new antifungal agents.
Antimicrobials: A Public Health Imperative
Dr. Rex frames antimicrobials as “the fire extinguishers of medicine,” essential for responding to infections quickly. However, the current economic model for antimicrobial development is fragile, with companies sometimes going out of business after bringing a drug to market due to insufficient revenue. Resistance is inevitable, highlighting the need for prevention, stewardship, and sustained innovation.
As fungal threats grow and the pipeline remains thin, a comprehensive strategy encompassing prevention, responsible use of existing drugs, and continued investment in research and development is crucial.